Alkermes said its experimental sleep drug ALKS 7290 showed proof of concept in an early-stage attention-deficit/hyperactivity disorder (ADHD) trial, with a Phase 2 study underway and results expected in 2027. Cue Biopharma reported positive Phase 2 results in China for CUE-221, an in-licensed treatment for chronic spontaneous urticaria, although its shares fell nearly 25% after the announcement. Eli Lilly said the U.S. Food and Drug Administration expanded Inluriyo’s use to combination treatment with Verzenio for certain patients with metastatic, estrogen receptor-positive, HER2-negative breast cancer. Johnson & Johnson said Caplyta reduced manic symptoms in a late-stage bipolar I disorder study, while AbbVie agreed to a multiyear partnership with Iambic to use artificial intelligence in discovering medicines for cancer, immune diseases and neurological conditions.